Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | NCK1 | P16333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21129799 | 0.85 | BACE1 (0.55) | BACE1TERTHTTPABPC1KDM4E | |
| SCHEMBL5775666 | 0.80 | BACE1 (0.57) | BACE1HTTPABPC1PSMB5KDM4E | |
| SCHEMBL29847851 | 0.80 | KDM4E (0.57) | BACE1TERTHTTKDM4EMEN1 | |
| SCHEMBL14702032 | 0.80 | NCK1 (0.57) | BACE1TERTPSMB5KDM4EMEN1 | |
| SCHEMBL11872346 | 0.80 | TDP1 (0.62) | BACE1TERTHTTPABPC1PSMB5 | |
| SCHEMBL21988721 | 0.77 | BACE1 (0.53) | BACE1HTTPABPC1KDM4EMEN1 | |
| SCHEMBL1128599 | 0.77 | BACE1 (0.44) | BACE1TERTHTTPABPC1PSMB5 | |
| SCHEMBL31028691 | 0.77 | BACE1 (0.53) | BACE1TERTHTTPABPC1PSMB5 | |
| SCHEMBL28539313 | 0.76 | PDE10A (0.53) | BACE1HTTPSMB5KDM4EALDH1A1 | |
| SCHEMBL22521603 | 0.74 | NPC1 (0.47) | BACE1TERTHTTPSMB5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4103558-A1 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163344-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021163344-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | BACE1 3093/4885TERT 356/4885HTT 3702/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | BACE1 1146/4885TERT 1150/4885HTT 1093/4885 |
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | BACE1 1501/4885TERT 4020/4885HTT 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.